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In 2014, the Task Force on Myocardial Revascularization of the European Society of Cardi-
ology and the European Association for Cardio-Thoracic Surgery with the special contribution
of the European Association of Percutaneous Cardiovascular Interventions published a com-
prehensive set of recommendations on myocardial revascularization in patients presenting with
acute or chronic coronary artery disease. In the United States, pertinent guidance on this topic
has been published by the American College of Cardiology, American Heart Association and
other relevant societies in multiple guideline documents that have been published in recent
years. This document brings together European and American recommendations on myocar-
dial revascularization with a focus on the role of cardiac imaging (J Nucl Cardiol 2017)
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Abbreviations
CABG Coronary artery bypass grafting
CAD Coronary artery disease
CTA Computed tomographic angiography
EF Ejection fraction
FFR Fractional flow reserve
HFrEF Heart failure with reduced ejection
fraction
ICD Implantable cardioverter defibrillator
LAD Left anterior descending coronary
artery
LIMA Left internal mammary artery
LOE Level of evidence
LV Left ventricular
MPS Myocardial perfusion scintigraphy
MRI Magnetic resonance imaging




Non-ST-segment elevation acute coro-
nary syndrome
PCI Percutaneous coronary intervention
PET Positron emission tomography
SIHD Stable ischaemic heart disease
SPECT Single-photon emission computed
tomography
STEMI ST-segment elevation myocardial
infarction
In 2014, the Task Force on Myocardial Revascu-
larization of the European Society of Cardiology (ESC)
and the European Association for Cardio-Thoracic
Surgery (EACTS) with the special contribution of the
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European Association of Percutaneous Cardiovascular
Interventions (EAPCI) published a comprehensive set of
recommendations on myocardial revascularization in
patients presenting with acute or chronic coronary artery
disease (CAD).1 In the United States, pertinent guidance
on this topic has been published by the American College
of Cardiology (ACC), American Heart Association
(AHA), and other relevant societies in multiple guideline
documents that have been published in recent years.2–10
This document brings together European and American
recommendations on myocardial revascularization for
side-by-side comparison; class (I, II or III) and level of
evidence (A, B or C) are shown for each recommendation
(Tables 1, 2, 3, 4, 5, 6 and Figures 1, 2). This is followed
by two Editorial comments that reflect on the similarities
and the differences between European and American
guidance and the relevance of these to clinical practice.
This represents the second of a new series of comparative
guidelines review; the first of these focused on the
recently published ACC/AHA and ESC/ESA guidelines
for the cardiovascular evaluation and management of
patients undergoing non-cardiac surgery.11–13
Table 1. Indications for diagnostic imaging in patients with suspected CAD
Recommendation
ESC/EACTS ACC/AHA
Class LOE Class LOE
Functional imaging* is recommended in patients with intermediate probability of
CAD1,2
I A I B
Invasive angiography is recommended in patients with
ESC: high probability of CAD1
ACC/AHA: unacceptable ischemic symptoms despite optimal medical therapy and
who are amenable to, and candidates for, coronary revascularization3
I A I C
CTA is recommended in patients with intermediate probability of disease1,2 IIa A II§ B
Combined or hybrid imagingII is recommended in patients with intermediate
probability of CAD1
IIa B NSER
Invasive angiography is reasonable to define the extent and severity of CAD in
patients with suspected SIHD whose clinical characteristics and non-invasive
testing (exclusive of stress testing) results indicate a high likelihood of severe IHD
and who are amenable to, and candidates for, coronary revascularization3
NSER IIa C
Invasive angiography is reasonable in patients with suspected symptomatic SIHD
who cannot undergo diagnostic stress testing, or have indeterminate or non-
diagnostic stress tests, when there is a high likelihood that the findings will result
in important changes to therapy3
NSER IIa C
Invasive angiography is recommended in patients with intermediate probability of
CAD1
IIb A NSER
Invasive angiography might be considered in patients with stress test results of
acceptable quality that do not suggest the presence of CAD when clinical
suspicion of CAD remains high and there is a high likelihood that the findings will
result in important changes to therapy3
NSER IIb C
Diagnostic imaging (invasive or non-invasive) is not recommended in asymptomatic
patients1,4
III A-C} III** C
Diagnostic imaging (invasive or non-invasive) is not recommended in patients with
low probability of CAD1,2
III A, C II$ B, C
III C
CTA is not recommended in patients with high probability of CAD1 III B NSER
Functional imaging is not recommended in patients with high probability of CAD1 III A, B NSER
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Table 1 continued
Recommendation ESC/EACTS ACC/AHA
Class LOE Class LOE
Combined or hybrid imaging is not recommended in patients with high probability
of CAD1
III B NSER
*Functional imaging refers to stress echocardiography, MPS, MRI, and PET imaging1
Probability of significant CAD: Low\15%; intermediate 15-85%; high[85%1
ACC/AHA guidelines stipulate intermediate to high probability of CAD in this circumstance2
§This is a class IIb recommendation for patients able to exercise and a IIa for patients unable to exercise2
kHybrid imaging refers to systems in which two imaging modalities are combined in the same scanner (e.g., multidetector CT and
SPECT, multidetector CT and PET)
}LOE A for invasive angiography, stress echocardiography, and MPS; LOE B for CTA, stress MRI, and PET; LOE C for combined or
hybrid imaging
**Per ACC/AHA guidelines, MPS may be considered in asymptomatic adults with diabetes or a strong family history of CAD, or
when previous risk assessment testing suggests high risk of CAD (class IIb, LOE C)4
LOE A for invasive angiography, stress echocardiography, and MPS; LOE C for CTA, stress MRI, PET, and combined or hybrid
imaging
$ACC/AHA guidelines state that, in patients with low probability of CADwho are incapable of at least moderate physical exertion,
CTA is a class IIa, LOE B. In patients who require testing, exercise or pharmacologic echocardiography is class II, LOE C. Exercise
MPS and pharmacologic stress with MPS, echocardiography, or MRI are class III in patients with an interpretable ECG who are
capable of at least moderate physical exertion
LOE A for stress echocardiography and MPS; LOE B for stress MRI, PET, and combined or hybrid imaging
Table 2. Indications for revascularization in patients with stable angina or silent ischemia according to
the extent of CAD
Recommendation
ESC/EACTS ACC/AHA
Class LOE Class LOE
For symptoms, revascularization is recommended for
Any significant coronary stenosis* in the presence of limiting angina or angina
equivalent that does not respond to medical therapy1,5
I A I A
For prognosis, revascularization is recommended for
Significant left main stenosis1,5 I A I B
Any significant proximal LAD stenosis1,5 I A I B
Survivors of sudden cardiac death with presumed ischemia-mediated ventricular
tachycardia caused by significant stenosis in a major coronary artery5
NSER I C
Two-vessel or three-vessel CAD with significant stenosis and impaired LV
function1,5
I A II B
Severe or extensive ischemia§1,5 I B IIa B
Single remaining patent coronary artery with significant stenosis1 I C NSER
Extensive anterior wall ischemia on non-invasive testing and previous CABG5 NSER IIb B
Significant stenoses in two major coronary arteries not involving the proximal LAD
and without extensive ischemia5,6
NSER IIb C
Revascularization is not recommended in patients with one or more coronary
stenoses that are not functionally or anatomically significant, involve only the left
circumflex or right coronary artery, or subtend only a small area of viable
myocardium5
NSER III B
*Defined in the ESC guidelines as coronary diameter stenosis[50% with documented ischemia on imaging, or FFR B0.80 for
diameter stenosis\90%;1 and in the ACC/AHA guidelines as C50% left main or C70% non-left main or FFR B0.80 stenosis5
This indication is ACC/AHA class I in the context of multivessel CAD, and class II in single-vessel disease
LVEF\40% (ESC guidelines)1. This indication is ACC/AHA class IIa in patients with mild-moderate LV dysfunction (LVEF, 35-50%)
and class IIb in patients with severe LV dysfunction (LVEF,\35%) without significant left main CAD5
§Defined as[10% ischemic LV myocardium (ESC guidelines)1, or[20% perfusion defect on stress MPS, high-risk criteria on stress
testing or abnormal intracoronary hemodynamic evaluation (ACC/AHA guidelines)5
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Table 3. Recommendations for non-invasive evaluation before revascularization in patients present-
ing with an acute coronary syndrome
Recommendation
ESC/EACTS ACC/AHA
Class LOE Class LOE
Non-invasive documentation of inducible ischemia in low-risk NSTE-ACS patients
without recurrent symptoms is recommended before deciding on invasive
evaluation1,7
I A I B
Non-invasive testing for ischemia should be performed before discharge in patients
with STEMI who have not had coronary angiography and do not have high-risk
clinical features for which coronary angiography would be warranted8
NSER I B
In initially stabilized patients, an ischemia-guided strategy may be considered for
patients with NSTE-ACS (without serious comorbidities or contraindication to this
approach) who have an elevated risk for clinical events7
NSER IIb B
PCI of a totally occluded infarct artery[24 hours after STEMI should not be
performed in asymptomatic patients with one- or two-vessel CAD if patients are
haemodynamically and electrically stable and do not have evidence of severe
ischemia8
NSER* III B
*According to ESC guidance, ‘‘in patients presenting days after an acute event, only those with recurrent angina or documented
residual ischemia and proven viability on non-invasive imaging in a large myocardial territory may be considered for revascu-
larization when the infarct artery is occluded’’1
Table 4. Recommendations on revascularization in patients with chronic heart failure and systolic LV
dysfunction according to the presence of viable and /or scarred myocardium
Recommendation
ESC/EACTS ACC/AHA
Class LOE Class LOE
Myocardial revascularization should be considered in the presence of viable
myocardium*1,5,9
IIa B IIa B
CABG with surgical ventricular restoration may be considered in patients with
scarred LAD territory1,9
IIb B IIb B
PCI may be considered if anatomy is suitable, in the presence of viable myocardium,
and surgery is not indicated1
IIb C NSER
CABG might be considered with the primary or sole intent of improving survival in
patients with SIHD and severe LV systolic dysfunction (EF,\35%) whether or not
viable myocardium is present5,6
NSER§ IIb B
*According to ESC guidelines, ‘‘nuclear imaging techniques have a high sensitivity for the detection of viability whereas tech-
niques evaluating contractile reserve have lower sensitivity but higher specificity. Differences in performance between the
various techniques are small; experience and availability often determine which technique is used’’1
CABG is recommended to improve survival in patients with a) target vessels supplying a large area of viable myocardium; b)
mild to moderate LV systolic dysfunction (LVEF, 35-50%) and significant multivessel CAD or proximal LAD stenosis when viable
myocardium is present in the region of intended revascularization5,6
‘‘Especially if a post-operative LV end-systolic volume index\70mL/m2 can be predictably achieved’’ 1. ACC/AHA guidelines
discuss surgical reverse remodeling or LV aneurysmectomy in isolation, with a IIb recommendation in carefully selected patients
with HFrEF for specific indications, including intractable heart failure and ventricular arrhythmias9
§ESC guidelines recommend CABG to improve prognosis in patients with severe LV dysfunction and significant LAD stenosis and
multivessel CAD but do not specify the state of viability (class I, LOE B)1
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Table 5. Recommendations for stress testing and ischemia-guided revascularization in special groups
Recommendation
ESC/EACTS ACC/AHA
Class LOE Class LOE
In stable patients with diabetes, multivessel CAD, and/or evidence of myocardial
ischemia, revascularization is indicated to reduce cardiac adverse events1,5
I B IIa* B
Repeat revascularization is indicated in post-CABG patients with severe symptoms
or extensive ischemia despite medical therapy if technically feasible1,5
I B II C
Stress testing should be considered in patients with a primary indication for CABG
and moderate mitral valve regurgitation to determine the extent of ischemia and
regurgitation1
IIa C NSER
In patients with CAD and LVEF\35%, testing for residual ischemia and subsequent
revascularization should be considered prior to primary prophylactic ICD
implantation1
IIa B NSER
Prophylactic myocardial revascularization before high-risk vascular surgery may be
considered in stable patients if they have persistent signs of extensive ischemia or
are at high cardiac risk
IIb B NSER§
*This indication refers to the preference of CABG over PCI in patients with diabetes and multivessel disease, particularly if a LIMA
graft can be anastomosed to the LAD artery5,6
This is a class IIa indication for PCI and class IIb for repeat CABG5,6
High cardiac risk (reported cardiac risk[5%): (1) aortic and other major vascular surgery; (2) peripheral vascular surgery1
§Revascularization before non-cardiac surgery is recommended when indicated by existing clinical practice guidelines10
Table 6. Strategies for follow-up and management after myocardial revascularization
Recommendation
ESC/EACTS ACC/AHA
Class LOE Class LOE
Asymptomatic patients
Early stress testing with imaging should be considered in specific patient subsets* IIa C NSER
Routine stress testing may be considered[2 years after PCI and[5 years after
CABG1
IIb C IIa C
Standard exercise ECG performed C1-year intervals might be considered in
patients with prior evidence of silent ischemia, or at high risk for a recurrent
cardiac event who can exercise and have an interpretable ECG2
NSER IIb C
Control angiography (CTA or invasive) within 3-12 months of high-risk PCI (e.g.,
unprotected left main stenosis) may be considered, irrespective of symptoms1
IIb C NSER
Symptomatic patients
Stress testing is recommended in patients with new or worsening symptoms not
consistent with unstable angina2,11
I C I B
It is recommended to reinforce medical therapy and lifestyle changes in patients
with low-risk findings (e.g.,\5% ischemic myocardium) on stress testing1,11
I C NSER
Coronary angiography is recommended in patients with intermediate-to-high-risk
findings§ on stress testing1
I C NSER
CTA for assessment of patency of CABG or of coronary stents C3 mm in diameter
might be reasonable in patients with new or worsening symptoms not consistent
with unstable angina irrespective of ability to exercise2
NSER IIb B
CTA might be reasonable in patients with new or worsening symptoms not
consistent with unstable angina in the absence of known moderate or severe
calcification or to assess patency of coronary stents\3 mm in diameter,
irrespective of ability to exercise2
NSER IIb B
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Table 6 continued
Recommendation ESC/EACTS ACC/AHA
Class LOE Class LOE
CTA is not recommended for the assessment of native coronary arteries with
known moderate or severe calcification or with coronary stents\3 mm in
diameter in patients with new or worsening symptoms not consistent with
unstable angina, irrespective of ability to exercise2
NSER III B
*This includes the following: High-safety professions (e.g., pilots, drivers, divers), competitive athletes, patients engaging in
strenuous recreational activities, sudden death survivors, patients with diabetes—especially if insulin-requiring, patients with
incomplete or suboptimal revascularization, complicated course during revascularization, or multivessel CAD and residual
intermediate lesions or with silent ischemia1
This recommendation is specific to the assessment of patients with prior evidence of silent ischemia or who are at high risk for a
recurrent cardiac event and (a) are unable to exercise adequately, or (b) have an uninterpretable ECG, or (c) have a history of
incomplete coronary revascularization2
According to ESC guidelines, stress imaging (stress MPS, echocardiography or MRI) is preferred over the exercise ECG14. ACC/
AHA guidelines recommend standard exercise ECG in patients who are able to exercise and have an interpretable ECG. Stress
imaging is indicated in patients with an uninterpretable ECG and in those unable to exercise adequately. Stress imaging is also
reasonable in patients who (a) previously required imaging with exercise stress, or (b) have known multivessel CAD, or (c) have a
high risk for multivessel CAD (class IIa, LOE B)2
§Ischemia at low workload, early onset ischemia, multiple areas of high-grade wall motion abnormality, or reversible perfusion
defect1
Figure 1. Indications for coronary revascularization in patients with suspected obstructive CAD
per ESC/EACTS and ACC/AHA guidelines. *CTA and stress echocardiography are ACC/AHA
class II indication. Defined as[50% coronary diameter stenosis with documented ischaemia on
non-invasive imaging, or FFR B 0.80 for diameter stenosis\90% (ESC guidelines); C50% left
main, or C70% non-left main, or FFR B0.80 stenosis (ACC/AHA guidelines). This is a class IIb
indication in patients with LVEF\35%. CABG, coronary artery bypass grafting; CAD, coronary
artery disease; LAD, left anterior descending; LM, left main.
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